Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
48.87
+2.13 (4.56%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cytokinetics Employees
Cytokinetics had 423 employees as of December 31, 2023. The number of employees increased by 14 or 3.42% compared to the previous year.
Employees
423
Change (1Y)
14
Growth (1Y)
3.42%
Revenue / Employee
$7,610
Profits / Employee
-$1,362,652
Market Cap
5.77B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 423 | 14 | 3.42% |
Dec 31, 2022 | 409 | 156 | 61.66% |
Dec 31, 2021 | 253 | 69 | 37.50% |
Dec 31, 2020 | 184 | 28 | 17.95% |
Dec 31, 2019 | 156 | 26 | 20.00% |
Dec 31, 2018 | 130 | -7 | -5.11% |
Dec 31, 2017 | 137 | 10 | 7.87% |
Dec 31, 2016 | 127 | 27 | 27.00% |
Dec 31, 2015 | 100 | 8 | 8.70% |
Dec 31, 2014 | 92 | 7 | 8.24% |
Dec 31, 2013 | 85 | 15 | 21.43% |
Dec 31, 2012 | 70 | -9 | -11.39% |
Dec 31, 2011 | 79 | -26 | -24.76% |
Dec 31, 2010 | 105 | -6 | -5.41% |
Dec 31, 2009 | 111 | 1 | 0.91% |
Dec 31, 2008 | 110 | -51 | -31.68% |
Dec 31, 2007 | 161 | 13 | 8.78% |
Dec 31, 2006 | 148 | -2 | -1.33% |
Dec 31, 2005 | 150 | -20 | -11.76% |
Dec 31, 2004 | 170 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
RadNet | 8,441 |
Merit Medical Systems | 6,950 |
Stevanato Group | 5,634 |
Tempus AI | 1,952 |
Inspire Medical Systems | 1,011 |
Ionis Pharmaceuticals | 927 |
Blueprint Medicines | 655 |
BridgeBio Pharma | 556 |
CYTK News
- 1 day ago - Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China - GlobeNewsWire
- 18 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction - GlobeNewsWire
- 19 days ago - Cytokinetics to Participate in December Investor Conferences - GlobeNewsWire
- 19 days ago - Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire
- 4 weeks ago - Bayer acquires rights to Cytokinetics' heart drug in Japan - Reuters
- 4 weeks ago - Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan - GlobeNewsWire
- 5 weeks ago - Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 - GlobeNewsWire